(Q38078271)

28 August 2017

1 reference

title

Mitogen-activated protein kinases as therapeutic targets for rheumatoid arthritis (English)

1 reference

28 August 2017

0 references

Verica Paunovic

1

1 reference

PubMed ID

23371304

28 August 2017

Margaret M Harnett

series ordinal

2

1 reference

28 August 2017

1 February 2013

1 reference

28 August 2017

1 reference

28 August 2017

73

1 reference

28 August 2017

2

1 reference

28 August 2017

101-115

1 reference

https://scigraph.springernature.com/pub.10.1007/s40265-013-0014-6

28 August 2017

0 references

cites work

The pathogenesis of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0014-6

Cytokines in the pathogenesis of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0014-6

Evidence that cytokines play a role in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0014-6

Mechanisms of disease: the molecular and cellular basis of joint destruction in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0014-6

Contribution of patient related differences to multidrug resistance in rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0014-6

Biologics-based therapy for the treatment of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0014-6

Effects of interleukin (IL)-17A and IL-17F in human rheumatoid arthritis synoviocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0014-6

p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0014-6

Small molecular therapies for rheumatoid arthritis: where do we stand?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0014-6

Differential signalling during B-cell maturation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0014-6

Interleukin-17 family members and inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0014-6

Differential regulation of interleukin-12 p40 and p35 induction via Erk mitogen-activated protein kinase-dependent and -independent mechanisms and the implications for bioactive IL-12 and IL-23 responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0014-6

A protein kinase involved in the regulation of inflammatory cytokine biosynthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0014-6

MAP kinases in the immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0014-6

Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0014-6

Activation mechanism of the MAP kinase ERK2 by dual phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0014-6

MAP kinases and the control of nuclear events

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0014-6

Signalling specificity of Ser/Thr protein kinases through docking-site-mediated interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0014-6

Molecular recognitions in the MAP kinase cascades

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0014-6

Unique MAP Kinase binding sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0014-6

Irreversible inhibitors of serine, cysteine, and threonine proteases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0014-6

Regulation of MAP Kinase Signaling Modules by Scaffold Proteins in Mammals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0014-6

Differential regulation and properties of MAPKs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0014-6

Identification of an oncoprotein- and UV-responsive protein kinase that binds and potentiates the c-Jun activation domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0014-6

c-Jun N-terminal kinase (JNK) positively regulates NFATc2 transactivation through phosphorylation within the N-terminal regulatory domain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0014-6

MEKK1/JNK signaling stabilizes and activates p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0014-6

TAB-1 modulates intracellular localization of p38 MAP kinase and downstream signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0014-6

Extracellular signals and scores of phosphatases: all roads lead to MAP kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0014-6

The specificity of extracellular signal-regulated kinase 2 dephosphorylation by protein phosphatases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0014-6

MKP-7, a novel mitogen-activated protein kinase phosphatase, functions as a shuttle protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0014-6

Both nuclear-cytoplasmic shuttling of the dual specificity phosphatase MKP-3 and its ability to anchor MAP kinase in the cytoplasm are mediated by a conserved nuclear export signal

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0014-6

Positive regulation of immune cell function and inflammatory responses by phosphatase PAC-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0014-6

Outcome measures in inflammatory rheumatic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0014-6

Epidermal growth factor increases prostaglandin E2 production via ERK1/2 MAPK and NF-kappaB pathway in fibroblast like synoviocytes from patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0014-6

Interleukin-32gamma enhances the production of IL-6 and IL-8 in fibroblast-like synoviocytes via Erk1/2 activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0014-6

c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0014-6

Induction of matrix metalloproteinase-13 gene expression by TNF-alpha is mediated by MAP kinases, AP-1, and NF-kappaB transcription factors in articular chondrocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0014-6

Central role of the MEK/ERK MAP kinase pathway in a mouse model of rheumatoid arthritis: potential proinflammatory mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0014-6

ERK-dependent T cell receptor threshold calibration in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0014-6

A multitude of kinases--which are the best targets in treating rheumatoid arthritis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0014-6

Identification of a selective ERK inhibitor and structural determination of the inhibitor-ERK2 complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0014-6

ERK inhibitors as a potential new therapy for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0014-6

Tpl2/cot signals activate ERK, JNK, and NF-kappaB in a cell-type and stimulus-specific manner.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0014-6

TNF-alpha induction by LPS is regulated posttranscriptionally via a Tpl2/ERK-dependent pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0014-6

Pharmacologic inhibition of tpl2 blocks inflammatory responses in primary human monocytes, synoviocytes, and blood.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0014-6

Inhibitors of tumor progression loci-2 (Tpl2) kinase and tumor necrosis factor alpha (TNF-alpha) production: selectivity and in vivo antiinflammatory activity of novel 8-substituted-4-anilino-6-aminoquinoline-3-carbonitriles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0014-6

Inhibition of interleukin-1-stimulated MAP kinases, activating protein-1 (AP-1) and nuclear factor kappa B (NF-kappa B) transcription factors down-regulates matrix metalloproteinase gene expression in articular chondrocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0014-6

Expression of the MAPK kinases MKK-4 and MKK-7 in rheumatoid arthritis and their role as key regulators of JNK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0014-6

Regulation of JNK by MKK-7 in fibroblast-like synoviocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0014-6

Regulation of inflammatory arthritis by the upstream kinase mitogen activated protein kinase kinase 7 in the c-Jun N-terminal kinase pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0014-6

Cep-1347 (KT7515), a semisynthetic inhibitor of the mixed lineage kinase family.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0014-6

JNK pathway: diseases and therapeutic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0014-6

SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0014-6

Design, synthesis, and biological activity of novel, potent, and selective (benzoylaminomethyl)thiophene sulfonamide inhibitors of c-Jun-N-terminal kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0014-6

Design and synthesis of the first generation of novel potent, selective, and in vivo active (benzothiazol-2-yl)acetonitrile inhibitors of the c-Jun N-terminal kinase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0014-6

JNK1, but not JNK2, is required in two mechanistically distinct models of inflammatory arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0014-6

JNK1 is not essential for TNF-mediated joint disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0014-6

p38 MAPK activity is stimulated by vascular endothelial growth factor receptor 2 activation and is essential for shear stress-induced angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0014-6

Growth inhibition by CDK-cyclin and PCNA binding domains of p21 occurs by distinct mechanisms and is regulated by ubiquitin-proteasome pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0014-6

The p38 and Hog1 SAPKs control cell cycle progression in response to environmental stresses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0014-6

The p57 CDKi integrates stress signals into cell-cycle progression to promote cell survival upon stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0014-6

A novel function of p38-regulated/activated kinase in endothelial cell migration and tumor angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0014-6

Interleukin (IL)-17 enhances tumor necrosis factor-alpha-stimulated IL-6 synthesis via p38 mitogen-activated protein kinase in osteoblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0014-6

Effects of RWJ 67657, a p38 mitogen activated protein kinase (MAPK) inhibitor, on the production of inflammatory mediators by rheumatoid synovial fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0014-6

A novel mechanism for TNF-alpha regulation by p38 MAPK: involvement of NF-kappa B with implications for therapy in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0014-6

The p38 mitogen-activated protein kinase pathway regulates interleukin-6 synthesis in response to tumor necrosis factor in osteoblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0014-6

MKK3/6-p38 MAPK signaling is required for IL-1beta and TNF-alpha-induced RANKL expression in bone marrow stromal cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0014-6

The p38α MAPK positively regulates osteoblast function and postnatal bone acquisition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0014-6

The discovery of RPR 200765A, a p38 MAP kinase inhibitor displaying a good oral anti-arthritic efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0014-6

Inhibition of p38 mitogen-activated protein kinase prevents inflammatory bone destruction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0014-6

Differential tissue expression and activation of p38 MAPK alpha, beta, gamma, and delta isoforms in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0014-6

Suppression of the clinical and cytokine response to endotoxin by RWJ-67657, a p38 mitogen-activated protein-kinase inhibitor, in healthy human volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0014-6

Single-dose pharmacokinetics and pharmacodynamics of RWJ 67657, a specific p38 mitogen-activated protein kinase inhibitor: a first-in-human study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0014-6

Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0014-6

Selective p38alpha inhibitors clinically evaluated for the treatment of chronic inflammatory disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0014-6

Pamapimod, a novel p38 mitogen-activated protein kinase inhibitor: preclinical analysis of efficacy and selectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0014-6

Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0014-6

MAP kinase p38 inhibitors: clinical results and an intimate look at their interactions with p38alpha protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0014-6

Protein kinases as targets for anticancer agents: from inhibitors to useful drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0014-6

p38α mitogen-activated protein kinase inhibitors, a patent review (2005-2011).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0014-6

Biphenyl amide p38 kinase inhibitors 4: DFG-in and DFG-out binding modes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0014-6

Pathway to the clinic: inhibition of P38 MAP kinase. A review of ten chemotypes selected for development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0014-6

Discovery and evaluation of 7-alkyl-1,5-bis-aryl-pyrazolopyridinones as highly potent, selective, and orally efficacious inhibitors of p38alpha mitogen-activated protein kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0014-6

Indole-based heterocyclic inhibitors of p38alpha MAP kinase: designing a conformationally restricted analogue

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0014-6

Inhibition of p38: has the fat lady sung?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0014-6

The p38alpha kinase plays a central role in inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0014-6

Activation of p38 mitogen-activated protein kinase in spinal microglia is a critical link in inflammation-induced spinal pain processing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0014-6

p38 MAPK, microglial signaling, and neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0014-6

Newly diagnosed rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0014-6

Successful structure-based design of recent p38 MAP kinase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0014-6

Design and Synthesis of 4-Azaindoles as Inhibitors of p38 MAP Kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0014-6

Efficacy and safety of pamapimod in patients with active rheumatoid arthritis receiving stable methotrexate therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0014-6

p38alpha mitogen-activated protein kinase inhibitors: optimization of a series of biphenylamides to give a molecule suitable for clinical progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0014-6

Analgesic efficacy and safety of the novel p38 MAP kinase inhibitor, losmapimod, in patients with neuropathic pain following peripheral nerve injury: a double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0014-6

PKA-I holoenzyme structure reveals a mechanism for cAMP-dependent activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0014-6

The kinase p38 alpha serves cell type-specific inflammatory functions in skin injury and coordinates pro- and anti-inflammatory gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0014-6

Feedback control of the protein kinase TAK1 by SAPK2a/p38

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0014-6

Kinase inhibitors attract attention as oral rheumatoid arthritis drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0014-6

Skepinone-L is a selective p38 mitogen-activated protein kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0014-6

"Go upstream, young man": lessons learned from the p38 saga

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0014-6

New drugs beyond biologics in rheumatoid arthritis: the kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0014-6

Targeting innate immunity protein kinase signalling in inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0014-6

Antiinflammatory functions of p38 in mouse models of rheumatoid arthritis: advantages of targeting upstream kinases MKK-3 or MKK-6

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0014-6

Synoviocyte innate immune responses: TANK-binding kinase-1 as a potential therapeutic target in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0014-6

The role of scaffold proteins in JNK signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0014-6

Regulation of stress-induced cytokine production by pyridinylimidazoles; inhibition of CSBP kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0014-6

Design, synthesis, and biological evaluation of novel disubstituted dibenzosuberones as highly potent and selective inhibitors of p38 mitogen activated protein kinase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0014-6

Discovery of 4-(5-(cyclopropylcarbamoyl)-2-methylphenylamino)-5-methyl-N-propylpyrrolo[1,2-f][1,2,4]triazine-6-carboxamide (BMS-582949), a clinical p38α MAP kinase inhibitor for the treatment of inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0014-6

The macrophage response towards LPS and its control through the p38(MAPK)-STAT3 axis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0014-6

Signal integration by JNK and p38 MAPK pathways in cancer development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0014-6

Activation, differential localization, and regulation of the stress-activated protein kinases, extracellular signal-regulated kinase, c-JUN N-terminal kinase, and p38 mitogen-activated protein kinase, in synovial tissue and cells in rheumatoid arthr

21 January 2018

1 reference

12 December 2020

IL-1 mediates TNF-induced osteoclastogenesis

1 reference

12 December 2020

Oral p38 mitogen-activated protein kinase inhibition with BIRB 796 for active Crohn's disease: a randomized, double-blind, placebo-controlled trial

1 reference

12 December 2020

A controlled two-centre trial of parenteral methotrexate therapy for refractory rheumatoid arthritis

1 reference

12 December 2020

ATF-2 is preferentially activated by stress-activated protein kinases to mediate c-jun induction in response to genotoxic agents

1 reference

12 December 2020

Prevention of the onset and progression of collagen-induced arthritis in rats by the potent p38 mitogen-activated protein kinase inhibitor FR167653

1 reference

12 December 2020

Journey to the surface of the cell: Fos regulation and the SRE

1 reference

12 December 2020

TNF-α Mediates p38 MAP Kinase Activation and Negatively Regulates Bone Formation at the Injured Growth Plate in Rats

1 reference

12 December 2020

IL-6 is produced by osteoblasts and induces bone resorption

1 reference

12 December 2020

The role of p38 mitogen-activated protein kinase in IL-1 beta transcription

1 reference

12 December 2020

Integration of the NF-kappaB and mitogen-activated protein kinase/AP-1 pathways at the collagenase-1 promoter: divergence of IL-1 and TNF-dependent signal transduction in rabbit primary synovial fibroblasts

1 reference

12 December 2020

Dual specificity phosphatases: a gene family for control of MAP kinase function.

1 reference

12 December 2020

Efficacy of low-dose methotrexate in rheumatoid arthritis

1 reference

12 December 2020

Pathways by which interleukin 17 induces articular cartilage breakdown in vitro and in vivo

1 reference

12 December 2020

Design and synthesis of potent, selective, and orally bioavailable tetrasubstituted imidazole inhibitors of p38 mitogen-activated protein kinase

1 reference

12 December 2020

Disease-modifying activity of SB 242235, a selective inhibitor of p38 mitogen-activated protein kinase, in rat adjuvant-induced arthritis

1 reference

12 December 2020

Lipopolysaccharide signals activation of tumor necrosis factor biosynthesis through the ras/raf-1/MEK/MAPK pathway.

1 reference

12 December 2020

IL-18 induces monocyte chemotactic protein-1 production in macrophages through the phosphatidylinositol 3-kinase/Akt and MEK/ERK1/2 pathways

1 reference

12 December 2020

Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function

1 reference

12 December 2020

Novel p38α mitogen-activated protein kinase inhibitor shows analgesic efficacy in acute postsurgical dental pain

1 reference

12 December 2020

Induction of c-fos expression through JNK-mediated TCF/Elk-1 phosphorylation.

1 reference

12 December 2020

CEP-1347 (KT7515), an inhibitor of JNK activation, rescues sympathetic neurons and neuronally differentiated PC12 cells from death evoked by three distinct insults

1 reference

12 December 2020

JNK inhibition as a potential strategy in treating Parkinson's disease.

1 reference

12 December 2020

Role of CSB/p38/RK stress response kinase in LPS and cytokine signaling mechanisms

1 reference

12 December 2020

Pyridinyl imidazoles inhibit IL-1 and TNF production at the protein level

1 reference

12 December 2020

VX-745. Vertex Pharmaceuticals

1 reference

12 December 2020

The yins of T cell activation

1 reference

12 December 2020

1 reference

12 December 2020

A 24-week, randomized, double-blind, placebo-controlled, parallel group study of the efficacy of oral SCIO-469, a p38 mitogen-activated protein kinase inhibitor, in patients with active rheumatoid arthritis

1 reference

12 December 2020

A selective p38 alpha mitogen-activated protein kinase inhibitor reverses cartilage and bone destruction in mice with collagen-induced arthritis

1 reference

12 December 2020

Involvement of p38 mitogen-activated protein kinase signaling pathway in osteoclastogenesis mediated by receptor activator of NF-kappa B ligand (RANKL)

1 reference

12 December 2020

In vivo selective inhibition of mitogen-activated protein kinase kinase 1/2 in rabbit experimental osteoarthritis is associated with a reduction in the development of structural changes

1 reference

12 December 2020

FR180204, a novel and selective inhibitor of extracellular signal-regulated kinase, ameliorates collagen-induced arthritis in mice

1 reference

12 December 2020

Extracellular signal-related kinase (ERK) and p38 mitogen-activated protein (MAP) kinases differentially regulate the lipopolysaccharide-mediated induction of inducible nitric oxide synthase and IL-12 in macrophages: Leishmania phosphoglycans subver

1 reference

12 December 2020

Direct Inhibition of Cyclooxygenase-1 and -2 by the Kinase Inhibitors SB 203580 and PD 98059

1 reference

12 December 2020

Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial

1 reference

12 December 2020

10.1007/S40265-013-0014-6

Identifiers

DOI

1 reference

PubMed ID

23371304

Dimensions Publication ID

28 August 2017

0 references

1 reference

PubMed ID

23371304